Literature DB >> 9377577

Genomic imprinting and Igf2 influence liver tumorigenesis and loss of heterozygosity in SV40 T antigen transgenic mice.

R Haddad1, W A Held.   

Abstract

Maternal-specific loss of heterozygosity (LOH) and allelic imbalances [i.e., partial LOH (pLOH)] observed in SV40 T/t antigen-induced liver tumors suggests that an imprinted gene on chromosome 7 is involved in liver tumorigenesis. Maternal-specific LOH/pLOH may reflect the loss of a maternally expressed tumor suppressor gene or the acquisition of paternally active alleles of a growth promoter. In addition, two oppositely imprinted genes on distal chromosome 7, Igf2 and H19, are re-expressed in most liver tumors from an SV40 T/t antigen transgenic line (M11T-G). Igf2 is a paternally expressed growth promoter, and H19 is a maternally expressed gene that can suppress growth in some tumor cell lines. We studied the role of Igf2 during liver tumorigenesis by creating Igf2 (+/-) M11T-G mice. These mice are essentially null for Igf2 expression because imprinting normally precludes maternal Igf2 expression. M11T-G, Igf2 (+/-) males exhibit a 15-fold reduction in the frequency of large tumors. Igf2 (+/-) tumors do not express maternal Igf2, indicating rigid imprinting control in the liver. LOH/pLOH analysis was performed on the tumors and indicates that acquisition of paternally active Igf2 alleles is a major selective event for M11T-G liver tumorigenesis. This also implies the existence of an imprinted, maternally expressed tumor suppressor gene on chromosome 7 that is unlikely to be H19.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377577

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  [Molecular mechanisms of progression in human hepatocarcinogenesis].

Authors:  K Breuhahn
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Induction of hepatocellular carcinoma by in vivo gene targeting.

Authors:  Pei-Rong Wang; Mei Xu; Sara Toffanin; Yi Li; Josep M Llovet; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

3.  7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma.

Authors:  M Mateo; M Mollejo; R Villuendas; P Algara; M Sanchez-Beato; P Martínez; M A Piris
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

4.  Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming.

Authors:  Hui Ling Chen; Tao Li; Xin Wen Qiu; Jie Wu; Jian Qun Ling; Zhi Hong Sun; Weibo Wang; Wei Chen; Aiju Hou; Thanh H Vu; Andrew R Hoffman; Ji-Fan Hu
Journal:  EMBO J       Date:  2006-11-02       Impact factor: 11.598

5.  A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma.

Authors:  Xiaoming Yao; Ji-Fan Hu; Mark Daniels; Hadas Shiran; Xiangjun Zhou; Huifan Yan; Hongqi Lu; Zhilan Zeng; Qingxue Wang; Tao Li; Andrew R Hoffman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 6.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing.

Authors:  Heinz G Linhart; Haijiang Lin; Yasuhiro Yamada; Eva Moran; Eveline J Steine; Sumita Gokhale; Grace Lo; Erika Cantu; Mathias Ehrich; Timothy He; Alex Meissner; Rudolf Jaenisch
Journal:  Genes Dev       Date:  2007-12-01       Impact factor: 11.361

8.  Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1.

Authors:  D C Martin; J L Fowlkes; B Babic; R Khokha
Journal:  J Cell Biol       Date:  1999-08-23       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.